The relationship between gut microbiota and COVID-19 progression: new insights into immunopathogenesis and treatment

Wang, Man; Zhang, Yuan; Li, Chunmei; Chang, Wenguang; Zhang, Lei

doi:10.3389/fimmu.2023.1180336

Cited by 20 publications

(14 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When we split our COVID-19 group into those who had been administered antibiotics and those who had not, we found that, in our cohort, alpha diversity was actually increased in our untreated COVID-19 patients, while it was significantly reduced in those who had received antibiotics. Interestingly, one study found that alpha diversity too was negatively correlated with COVID-19 severity and poor prognosis ( Wang et al., 2023 ), suggesting another possible reason for the conflicting results reported in the literature. Therefore, it is possible that SARS-CoV-2 infection can have different effects on the alpha-diversity of the GM depending on how long the virus has infected the patient, and on how severe the infection is.…”

Section: Discussionmentioning

confidence: 99%

The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection

Piazzesi,

Pane,

Del Chierico

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

IntroductionSince the beginning of the SARS-CoV-2 pandemic in early 2020, it has been apparent that children were partially protected from both infection and the more severe forms of the disease. Many different mechanisms have been proposed to explain this phenomenon, including children’s frequent exposure to other upper respiratory infections and vaccines, and which inflammatory cytokines they are more likely to produce in response to infection. Furthermore, given the presence of SARS-CoV-2 in the intestine and its ability to infect enterocytes, combined with the well described immunomodulatory capabilities of the microbiome, another potential contributing factor may be the presence of certain protective microbial members of the gut microbiota (GM).MethodsWe performed shotgun metagenomic sequencing and profiled both the bacteriome and virome of the GM of pediatric SARS-CoV-2 patients compared to healthy, age-matched subjects.ResultsWe found that, while pediatric patients do share some pro-inflammatory microbial signatures with adult patients, they also possess a distinct microbial signature of protective bacteria previously found to be negatively correlated with SARS-CoV-2 infectivity and COVID-19 severity. COVID-19 was also associated with higher fecal Cytomegalovirus load, and with shifts in the relative abundances of bacteriophages in the GM. Furthermore, we address how the preventative treatment of COVID-19 patients with antibiotics, a common practice especially in the early days of the pandemic, affected the bacteriome and virome, as well as the abundances of antimicrobial resistance and virulence genes in these patients. DiscussionTo our knowledge, this is the first study to address the bacteriome, virome, and resistome of pediatric patients in response to COVID-19 and to preventative antibiotics use.

show abstract

Section: Discussionmentioning

confidence: 99%

The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection

Piazzesi,

Pane,

Del Chierico

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Intestinal barrier impairment, dysbiosis of gut microbiota, and perturbation of metabolites are prevalent occurrences among individuals with COVID‐19. Extensive research has consistently shown the association between microbiota composition and the morbidity, exacerbation, and mortality rates seen in COVID‐19 patients 51–55 . The gut microbiota facilitates the assessment of sickness severity in individuals with COVID‐19 56 .…”

Section: Discussionmentioning

confidence: 99%

“…patients. [51][52][53][54][55] The gut microbiota facilitates the assessment of sickness severity in individuals with COVID-19. 56 From a mechanical standpoint, it is observed that COVID-19 disrupts the composition of gut microbiota and metabolites.…”

Section: Potential Confounding Factors and Mechanismsmentioning

confidence: 99%

Eliminating COVID‐19 as the immediate culprit for igniting pancreatitis

Ge,

Luo,

Liu

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The impact of severe acute respiratory syndrome coronavirus 2 infection on the potential development of pancreatitis is a subject of ongoing debate within academic discourse. Establishing a causal link between COVID‐19 and pancreatitis may not be fully supported by relying only on retrospective studies or case reports. This study examined the relationship between COVID‐19 phenotypes and pancreatitis by Mendelian randomization (MR) method. The identification of instrumental variables (single nucleotide polymorphisms) that exhibit a robust association with the COVID‐19 phenotypes was accomplished through a meticulous process of rigorous screening procedures. We included acute pancreatitis and chronic pancreatitis (CP) as the outcomes in the MR analysis, even though no definitive studies exist between COVID‐19 and CP. A direct causal relationship between genetically predicted COVID‐19 phenotypes and pancreatitis risk cannot be established. There is an ongoing debate over the designation of COVID‐19 as a definitive cause of pancreatitis.

show abstract

“…The bidirectional regulation between the gut microbiota and host immunity may play an important role in this process. 109 In addition, SARS‐CoV‐2 may cause the disorder of gut microbiota, thereby increasing susceptibility to COVID‐19. The mechanisms by which the disturbance of gut microbiota increases susceptibility to COVID‐19 and associated symptoms are poorly understood.…”

Section: Dynamic Changes Of Microbiota In Covid‐19mentioning

confidence: 99%

Alterations in microbiota of patients with COVID‐19: implications for therapeutic interventions

Qiu,

Mo,

Chen

et al. 2024

MedComm

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) recently caused a global pandemic, resulting in more than 702 million people being infected and over 6.9 million deaths. Patients with coronavirus disease (COVID‐19) may suffer from diarrhea, sleep disorders, depression, and even cognitive impairment, which is associated with long COVID during recovery. However, there remains no consensus on effective treatment methods. Studies have found that patients with COVID‐19 have alterations in microbiota and their metabolites, particularly in the gut, which may be involved in the regulation of immune responses. Consumption of probiotics may alleviate the discomfort caused by inflammation and oxidative stress. However, the pathophysiological process underlying the alleviation of COVID‐19‐related symptoms and complications by targeting the microbiota remains unclear. In the current study, we summarize the latest research and evidence on the COVID‐19 pandemic, together with symptoms of SARS‐CoV‐2 and vaccine use, with a focus on the relationship between microbiota alterations and COVID‐19‐related symptoms and vaccine use. This work provides evidence that probiotic‐based interventions may improve COVID‐19 symptoms by regulating gut microbiota and systemic immunity. Probiotics may also be used as adjuvants to improve vaccine efficacy.

show abstract

The relationship between gut microbiota and COVID-19 progression: new insights into immunopathogenesis and treatment

Cited by 20 publications

References 135 publications

The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection

The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection

Eliminating COVID‐19 as the immediate culprit for igniting pancreatitis

Alterations in microbiota of patients with COVID‐19: implications for therapeutic interventions

Contact Info

Product

Resources

About